Clinical Decision Support Tool for Infliximab in Crohn's Disease

Parambir S Dulai; Emily C L Wong; Walter Reinisch; Neeraj Narula

doi:10.1016/j.cgh.2021.06.037

Clinical Decision Support Tool for Infliximab in Crohn's Disease

Clin Gastroenterol Hepatol. 2022 May;20(5):e1192-e1195. doi: 10.1016/j.cgh.2021.06.037. Epub 2021 Jun 30.

Authors

Parambir S Dulai¹, Emily C L Wong², Walter Reinisch³, Neeraj Narula²

Affiliations

¹ Division of Gastroenterology, University of California San Diego, La Jolla, California. Electronic address: pdulai@health.ucsd.edu.
² Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
³ Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

PMID: 34216825
DOI: 10.1016/j.cgh.2021.06.037

Abstract

Biologic treatment options for Crohn's disease (CD) are increasing and providers will need enhanced support in integrating these therapies into routine practice. Using phase 3 clinical trial programs in CD, we have previously built and validated clinical decision support tools for achieving clinical remission (CREM) with vedolizumab and ustekinumab in CD.^1-4 We now aim to develop a clinical decision support tool for infliximab in CD.

Trial registration: ClinicalTrials.gov NCT00094458 NCT02096861.

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Crohn Disease* / drug therapy
Decision Support Systems, Clinical*
Humans
Infliximab / therapeutic use
Ustekinumab / therapeutic use

Substances

Infliximab
Ustekinumab

Associated data

ClinicalTrials.gov/NCT00094458
ClinicalTrials.gov/NCT02096861